Explore how AI in high-throughput screening improves drug discovery through advanced data analysis, hit identification and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Master ultra-high-throughput screening principles. Learn how advanced automation and miniaturization accelerate drug ...
Drug discovery can be a long and complex process. Medicines for neurodegenerative diseases like Alzheimer's disease are among the most expensive to develop, as animal model results have not proven to ...
Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...
Combined market-leading speed and 27 channel capacity enable maximum flexibility and data generation New fluidics and clog detection systems further simplify operation and reduce instrument downtime ...
A research team from the University of Hong Kong has developed a general computational protocol for phosphorescent platinum(II) complexes via high throughput virtual screening and Δ-learning ...
Revvity offers comprehensive solutions designed to help accelerate laboratory workflows, assisting researchers meet targets faster and bring new therapies to market sooner. Our integrated approach ...
Optimized chemistry enables direct synthesis of up to 500 bp double stranded fragments “Using our chemical synthesis platform we are able to directly synthesize Twist Multiplexed Gene Fragments as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results